Pinealon

Pinealon is a synthetic tripeptide composed of glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg, single-letter code EDR). It belongs to the Khavinson Cytogen class developed at the St. Petersburg Institute of Bioregulation and Gerontology and is positioned as a neural-cognitive bioregulator with proposed origin in pineal-tissue peptide signaling. The clinical evidence base belongs almost entirely to the Khavinson research network.

The Khavinson bioregulator program produced two parallel compound classes. Cytomaxes are organ-specific peptide extracts containing heterogeneous mixtures. Cytogens are short synthetic peptides designed to reproduce a single defined active sequence. For the pineal-neural system, two Cytogens are widely marketed: Epitalon (the tetrapeptide AEDG, with primary longevity and circadian positioning) and Pinealon (the tripeptide EDR, with primary cognitive and neuroprotective positioning).

The two compounds share the EDR core. Epitalon adds an N-terminal alanine and a C-terminal glycine; Cardiogen adds only an N-terminal alanine. The sequence relationships suggest the EDR core carries the central biological activity, with the flanking residues modulating tissue distribution and stability. The Khavinson group has used this sequence-mining strategy across the Cytogen line.

The Evidence Base

The compound-specific clinical evidence includes:

Russian-institution clinical observation studies in elderly patients with cognitive complaints, cerebrovascular disease, and post-stroke cognitive recovery. Reports describe improvement in attention, working memory, and mood scales after 30-day courses.

Preclinical neuroprotection (Arutjunyan and colleagues, 2012). Studies in cultured neurons exposed to oxidative stress reported protective effects of Pinealon against neuronal death, with reduced apoptosis markers and improved viability.

Mechanism work in the broader Khavinson framework. The 2014 Khavinson review on peptide regulation of gene expression and the 2020 short-peptide DNA-interaction paper describe the proposed nuclear peptide binding model that applies across the Cytogen class, including Pinealon.

Independent Western replication is sparse. PubMed indexing for Pinealon-specific work returns Khavinson-affiliated publications. No registered ClinicalTrials.gov trial exists for Pinealon as of May 2026.

Regulatory and Legal Status

FDA. No approval. Not on bulk drug substances list.

EMA. No approval.

Russia. Registered as a biologically active dietary supplement. Sold in oral capsule format through the Khavinson distribution network.

WADA. Not on the 2026 Prohibited List.

The proposed mechanism follows the Khavinson short-peptide bioregulation model with neural-tissue specificity.

Cellular entry. EDR is hypothesized to enter neurons through peptide transporters (PEPT1, PEPT2), reach the cytoplasm, and translocate to the nucleus. The small molecular weight facilitates passive diffusion through nuclear pores.

Nuclear binding and gene expression. The Khavinson group has reported that short peptides including EDR bind selectively to specific DNA sequences in gene promoters. The 2020 short-peptide DNA-interaction paper extends this framework to the EDR motif. For Pinealon, the proposed target gene clusters include genes governing neuronal survival, synaptic protein expression, and stress-response pathways.

Neuroprotective effects. Preclinical work has documented:

• Reduced neuronal apoptosis under oxidative stress in cell culture
• Stabilization of mitochondrial function markers
• Reduction in beta-amyloid-induced neurotoxicity in neuronal cell cultures
• Effects on protein synthesis in aged neurons

Cognitive effects in animal models. Russian preclinical work has reported improvements in spatial memory in rodent models and protective effects in models of accelerated brain aging.

Comparison to Epitalon and Cardiogen. All three compounds share the EDR core. The functional distinctions described in Khavinson group work are:

• Epitalon (AEDG) — Telomerase activation, circadian rhythm, broad longevity effects
• Pinealon (EDR) — Direct neuroprotection, cognitive support, neuronal stress resistance
• Cardiogen (AEDR) — Cardiomyocyte-targeted effects

Whether these functional distinctions are robust or are constructed post-hoc from observed effects is debatable. The shared core sequence makes strict tissue specificity claims somewhat hard to defend mechanistically.

Pharmacokinetics. Oral tripeptides face gut hydrolysis. The Khavinson framework proposes partial PEPT1 absorption and signaling at the gut-mucosa interface. Direct measurement of intact Pinealon in plasma after oral administration is not published. Research-chemical subcutaneous and intranasal protocols bypass gut hydrolysis but lack pharmacokinetic characterization.

Human pharmacokinetic data is not published in any English-language peer-reviewed journal.

Russian-institution clinical reports describe:

• Improvement in attention and working memory in elderly subjects
• Reduction in self-reported anxiety and irritability scores
• Adjunct effects in post-stroke cognitive rehabilitation protocols
• Modulation of sleep-wake patterns and subjective sleep quality
• Improvement in markers of cerebrovascular reserve in patients with chronic cerebral ischemia

Research-chemical user reports include:

• Subjective improvement in mental clarity and verbal fluency
• Perceived reduction in age-related cognitive symptoms
• Mood-elevating effects in some users
• Reports of vivid dreams when used at higher doses or close to bedtime
• Possible synergistic effects when combined with Epitalon

User reports are uncontrolled and not verified for vial identity. The clinical observation data is non-blinded and produced within the Khavinson institutional network.

No standardized human dosing protocol supported by independent pharmacokinetic data exists for Pinealon.

The Russian retail product is dosed as 1 to 2 capsules once or twice daily before meals for a 30-day course, repeated 2 to 3 times per year. Each capsule contains approximately 20 mg of active peptide.

Research-chemical subcutaneous protocols typically use 100 to 500 mcg per day over 10 to 20 day cycles. Intranasal protocols, where used, employ similar daily totals delivered in divided doses. These protocols are extrapolated from generic Khavinson recommendations and lack Pinealon-specific human pharmacokinetic support.

The course-and-cycle pattern reflects the Khavinson framework, in which bioregulator effects are claimed to persist between courses through induced gene-expression changes. Optimal cycle spacing has not been independently validated for Pinealon.

The Khavinson bioregulator class has a benign published adverse-event profile. Russian manufacturer documentation lists individual intolerance, pregnancy, and lactation as contraindications. No serious adverse events have been reported in Russian-language clinical publications.

The constituent amino acids (glutamic acid, aspartic acid, arginine) are common dietary amino acids. Tripeptide doses at the microgram-to-milligram level fall within typical dietary peptide exposure. Acute toxicity is mechanistically unlikely.

Long-term human safety data with controlled endpoints does not exist for chronic Pinealon use over multiple years. Theoretical concerns specific to chronic high-dose use include:

• Effects on neuronal gene-expression homeostasis with sustained nuclear peptide-DNA interaction
• Possible interactions with conventional cognitive-enhancing medications (cholinesterase inhibitors, NMDA antagonists)
• Interactions with antidepressants (SSRIs, SNRIs, monoamine oxidase inhibitors)
• Effects on seizure threshold (Pinealon's putative neuroprotective mechanism has not been characterized for excitotoxicity-related effects)

Drug-drug interaction data is absent. The compound's safety in patients with active seizure disorders, ongoing psychiatric treatment, or cerebrovascular disease has not been formally evaluated.

Pinealon is most often paired with Epitalon in Khavinson protocols. The two compounds share the EDR core and have complementary positioning: Epitalon for systemic longevity and circadian effects, Pinealon for direct neural-cognitive support. This pairing is the most common Khavinson stack for cognitive applications.

For broader Khavinson neural-cognitive stacks, Pinealon is combined with Cerluten (brain Cytomax) and Cortexin (cerebral cortex Cytomax). The Cytogen-then-Cytomax sequence applies: Pinealon as the synthetic initial-phase compound, followed by the heterogeneous extract for extended support.

For broader nootropic comparisons, Pinealon is sometimes compared with Semax and Selank, the better-known Russian heptapeptide nootropics. The compounds differ substantially in sequence, mechanism, and evidence base. Semax and Selank have Russian regulatory approval as medical drugs; Pinealon is registered only as a dietary supplement. The mechanistic claims for Semax and Selank are receptor-based (BDNF and serotonergic modulation, respectively); Pinealon's claims are nuclear peptide-DNA binding.

External pharmaceutical comparators are diagnosis-specific. For mild cognitive impairment and Alzheimer's disease, FDA-approved cholinesterase inhibitors and memantine have Phase 3 evidence. For cerebrovascular cognitive decline, post-stroke rehabilitation, and vascular dementia, the conventional approach combines vascular risk factor management with rehabilitation. Pinealon has no comparable evidence base and is not a substitute for these established approaches in clinically significant cognitive disease.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.